A Study of Vaccine Therapy for Prostate Cancer Using Prostate Stem Cell Antigen (PSCA)-Transfected Dendritic Cells

点击翻译按钮获取中文摘要

To establish genetic immunotherapy for prostate cancer, using prostate stem cell antigen (PSCA) as a specific antigen, we previously cloned cDNA of mPSCA from mouse prostate glands using RT-PCR and attempted DNA vaccine therapy, with mouse prostate cancer cell lines (RM-1 and RM-11) serving as target cells. These previous studies indicated the necessity of establishing some other evaluation systems for the expression of mPSCA protein in mouse prostate cancer cell lines. To meet this need, we prepared, using retrovirus vectors, RM-1 cells (RM-1mPSCA, RM-1FLAGmPSCA) and RM-11 cells (RM-11mPSCA, RM-11FLAGmPSCA) which permanently express mPSCA or FLAG-conjugated mPSCA.The present study was undertaken to evaluate the usefulness of these cells as an evaluation system. To this end, differences in cell proliferation depending on the presence or absence of mPSCA and FLAGmPSCA expression were investigated in vitro. The proliferation of RM-1mPSCA, RM-1FLAGmPSCA, RM-11mPSCA and RM-11FLAGmPSCA depicted a curve similar to that of RM-1 and RM-11 proliferation. Then, proliferation of the cells was evaluated in vivo. Mice were subcutaneously implanted with RM-1, RM-1mPSCA or RM-1FLAGmPSCA and their proliferation was examined. No marked difference in proliferation was noted among these tumor cell lines.Thus, it was possible to compare the expression of these cell lines at the protein level. We may therefore say that this mouse model is useful for evaluation of DNA vaccine therapy or RNA vaccine therapy for prostate cancer, with mPSCA serving as the target.